top of page
_Horizontal_Full%20Colour.png){kind=small}
FY2024 HIGHLIGHTS
Advanced MedTech reports record global revenues of US$335 million in FY2024.
-
Advanced MedTech (“The Group”) saw a 15.1% growth compared to the previous year; sales increased 17.4% year-on-year, excluding COVID-19 related revenues, driven by strong performance in all segments.
-
United States entities grew revenue by 22.3%, making up 55.4% of total revenue and 65.3% of urology revenue.
-
From FY22 to FY24, the compound annual growth rate (CAGR) was 16.4%, excluding COVID-19 related revenues.
-
Recent groundbreaking product launches include the Thulio laser, AXIS II Family of Single-use Ureteroscopes and Cystoscopes, Wikkon E300 Shockwave Therapeutic Device, and UroGPT™ chatbot.
®
®
-
To support future innovation-led growth, the Group increased R&D investment in the year by more than 20%.
-
These advancements align with the Group’s customer-centric vision of providing a comprehensive Urology care experience through its Integrated Urology Platform (IUP) strategy.
Advanced MedTech is redefining Urological care with its Integrated Urology Platform (IUP), which unifies access to Dornier MedTech’s robust product lines, its comprehensive Clinical Urology Services and dynamic Community initiatives. This all-encompassing platform is designed to cater to the nuanced demands of both patients and urologists, setting a new standard in Urological care.
Capital Equipment
Develops, manufactures, markets and services a comprehensive portfolio of urological medical devices, such as innovative urology workstations, lithotripters and high-power lasers, for stone management, BPH and related urological conditions.
Consumables
Key complement to the capital equipment product line and clinical urology service business with a comprehensive premium consumables portfolio.
Clinical Urology Service
'Stone as a service' URS+ model in the United States, offering a one-stop service model which delivers equipment, expert technologists, consumables, maintenance and back-end management support.
Connected Digital Community
Robust digital platform that enhances urology patient education, fosters community engagement and optimizes care by connecting patients in the United States with top urologists. We collate and analyze our learnings from patient insights, sharing them with our treating urologists in order to improve their patient experience and outcomes.
Clinical Urology Service
'Stone as a service' URS+ model in the United States, offering a one-stop service model which delivers equipment, expert technologists, consumables, maintenance and back-end management support.
Consumables
Key complement to the capital equipment product line and clinical urology service business with a comprehensive premium consumables portfolio.
Capital Equipment
Develops, manufactures, markets and services a comprehensive portfolio of urological medical devices, such as innovative urology workstations, lithotripters and high-power lasers, for stone management, BPH and related urological conditions.
Connected Digital Community
Robust digital platform that enhances urology patient education, fosters community engagement and optimizes care by connecting patients in the United States with top urologists. We collate and analyze our learnings from patient insights, sharing them with our treating urologists in order to improve their patient experience and outcomes.
With its flywheel strategy, the IUP leverages Advanced MedTech’s extensive business offerings to offer compelling value to patients, providers and payors within the healthcare ecosystem.
Segment Highlights
Capital Equipment and
Consumables (CEC)
14.7%
CAGR (FY22-FY24)
Clinical Urology Services
(CUS)
16.7%
CAGR (FY22-FY24)
Robotic Surgery and Tools
(RST)
21.9%
CAGR (FY22-FY24)
Digital Community:
The Worst Pain Ever platform
>48mil
IMPRESSIONS
®
Capital Equipment and Consumables: Achieved revenues of US$163.6 million, a 15.0% revenue growth from the previous period and CAGR of 14.7% from FY22 to FY24 on the back of innovation-driven growth.
Clinical Urology Services: Recorded revenues of US$120.5 million, a 19.7% revenue growth compared to the previous period, with a CAGR of 16.7% from FY22 to FY24. Rapid expansion in the CUS segment saw more than 60,000 patient treatment procedures performed in FY24, a 14.5% year-over-year increase and an 11.0% CAGR over the last three fiscal years.
Robotic Surgery and Tools: Reported revenues of US$50.9 million, a 5.7% revenue growth from the previous period, or a 19.8% growth from the previous period excluding COVID-related revenues. Excluding COVID-related revenues, RST grew at a CAGR of 21.9% from FY22 to FY24.
Digital Community: The Worst Pain Ever platform continues to be the largest digital urology community, garnering over 48 million impressions annually from patients and caregivers on Facebook. In 2024, the platform expanded its offerings with the launch of UroGPT™, a pioneering AI chatbot designed to provide immediate, reliable guidance to kidney stone patients.
®
Digital Community: The Worst Pain
Ever platform continues to be the largest digital urology community, garnering over 48 million impressions annually from patients and caregivers on Facebook. In 2024, the platform expanded its offerings with the launch of UroGPT™, a pioneering AI chatbot designed to provide immediate, reliable guidance to kidney stone patients.
®
Product Highlights
THULIO
®
Thulio has rapidly expanded its global presence within the past
year, now reaching markets across Europe, the USA, Latin
America, Australia, Asia, and the Middle East. This expansion has
been accompanied by a significant surge in Thulio sales,
reflecting strong market confidence in our 100 W High Power
Pulsed Thulium:YAG Laser.
®
®
UroGPT™
Recognized for its unique potential to advance patient education and mitigate physician workload, UroGPT™ has been rapidly adopted for studies and clinical use at prestigious institutions, including Stanford Health and UCLA. It has also earned early endorsements from key industry figures, including the Chair of the American Urological Association Research Appropriations Committee.
UROGPT™
Recognized for its unique potential to advance patient education
and mitigate physician workload, UroGPT™ has been rapidly
adopted for studies and clinical use at prestigious institutions,
including Stanford Health and UCLA. It has also earned early
endorsements from key industry figures, including the Chair
of the American Urological Association Research Appropriations
Committee.
bottom of page